The MS Trust is delighted that Ocrevus (ocrelizumab) has been approved by NICE for NHS treatment of early, inflammatory primary progressive MS.
NICE has approved Ocrevus for people with primary progressive MS if they:
have had symptoms of primary progressive MS for 15 years or less
are able to walk 20 metres or more, with or without walking aids (up to EDSS 6.5)
have evidence of MS activity on MRI scans.
Browse categories and add by clicking on them
You can remove current categories below by clicking the ‘x’.